Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis : to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020

10/22/2020 | 04:08pm EST

– Conference Call and Webcast to Follow at 5:00 p.m. EST / 2:00 p.m. PST –

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2020 financial results will be released on Thursday, November 5, 2020 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 6945239 to join by phone.

A telephone replay will be available until 8:00 p.m. EST on November 7, 2020. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 6945239. A webcast replay will also be archived on www.exelixis.com for one year.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.


© Business Wire 2020
All news about EXELIXIS, INC.
01/22EXELIXIS : Gets FDA Approval for Kidney Cancer Treatment
MT
01/22EXELIXIS : Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combinati..
BU
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/11EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/11EXELIXIS : Reports Preliminary Q4 Revenue of $270 Million, Issues 2021 Guidance
MT
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2020 Financial Res..
BU
01/04EXELIXIS : to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conferen..
BU
2020EXELIXIS : Announces Cabozantinib Significantly Improved Progression-Free Surviv..
AQ
2020EXELIXIS : Phase 3 Study of Cabometyx in Thyroid Cancer Meets Co-Primary Endpoin..
MT
2020EXELIXIS : Announces Cabozantinib Significantly Improved Progression-Free Surviv..
BU
More news
Financials (USD)
Sales 2020 988 M - -
Net income 2020 99,7 M - -
Net cash 2020 1 494 M - -
P/E ratio 2020 75,9x
Yield 2020 -
Capitalization 6 869 M 6 869 M -
EV / Sales 2020 5,44x
EV / Sales 2021 4,23x
Nbr of Employees 617
Free-Float 98,0%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 30,83 $
Last Close Price 22,14 $
Spread / Highest target 67,1%
Spread / Average Target 39,3%
Spread / Lowest Target 12,9%
EPS Revisions
Managers and Directors
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.10.31%6 869
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148